LGD-4033 (Ligandrol)
Performance
View productThis site is an educational resource for research compounds. We do not endorse human consumption of any compound. We rank every vendor on the same public methodology, and we earn a commission on purchases through some of our links. By entering, you confirm you are 21 years of age or older and agree to our Terms & Privacy Policy.

Also known as: YK11, YK 11, Myostine, Steroidal SARM YK-11
YK-11 is a synthetic steroid, not a nonsteroidal SARM, despite being sold alongside them. Its full chemical name is methyl (17alpha,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylate, and it was described by an academic group at Toho University in Japan rather than by a pharmaceutical company.
YK-11 is a steroidal partial agonist of the androgen receptor. It binds the receptor and drives nuclear translocation, but does not induce the amino-terminal to carboxy-terminal interaction that full androgen agonists cause, which is thought to explain its partial and gene-select…
YK-11 is a synthetic steroid, not a nonsteroidal SARM, despite being sold alongside them. Its full chemical name is methyl (17alpha,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylate, and it was described by an academic group at Toho University in Japan rather than by a pharmaceutical company. It has never entered clinical development. There is no company behind it, no investigational new drug program, and no human trial of any kind. The original 2011 report showed that YK-11 activates the androgen receptor as a partial agonist in a reporter assay, moves the receptor into the nucleus, and does so without inducing the amino-terminal to carboxy-terminal interaction that full androgens produce. In androgen receptor positive human breast cancer cells it acted as a gene-selective agonist, so its effect relative to dihydrotestosterone depended on which gene was measured (PMID: 21372378). Later work from the same group traced that selectivity to different DNA binding and different co-regulator recruitment compared with dihydrotestosterone (PMID: 36030969). The claim that YK-11 is a myostatin inhibitor comes from one cell study. In mouse C2C12 myoblasts, YK-11 induced expression of follistatin, a protein that binds and neutralizes myostatin, and the resulting myogenic differentiation was reversed by an anti-follistatin antibody (PMID: 23995658). That is an indirect, cell-culture result in mouse cells. There is no published evidence that YK-11 binds or inhibits myostatin directly, and no human data on myostatin or follistatin after taking it. Other preclinical results include increased proliferation and mineralization in mouse MC3T3-E1 osteoblast cells (PMID: 29491216), improved osteogenic differentiation of rat bone marrow stromal cells and repair of rat cranial bone defects (PMID: 39660819), and reduced inflammatory markers and mortality in mice with bacterial sepsis (PMID: 33588136). The safety data that do exist are unfavorable and come from rats. In male Wistar rats, five weeks of YK-11 increased oxidative stress and impaired every measured marker of mitochondrial function in the hippocampus, and exercise did not reverse those changes (PMID: 37468001). A follow-up study in rats reported impaired memory consolidation, downregulation of BDNF signaling, higher pro-inflammatory interleukin 1 beta and interleukin 6, lower interleukin 10, and activation of an apoptotic cascade in the hippocampus (PMID: 38521455). There is no human safety data at all. In sport, YK-11 is prohibited. It is named in the World Anti-Doping Agency anabolic agents class alongside the nonsteroidal SARMs (PMID: 28137616), its mass spectrometric behavior and human urinary metabolites have been characterized for testing (PMID: 28440570, PMID: 30379415), and it has been reported in an actual doping control sample (PMID: 37946705). FDA has named YK-11 in warning letters to firms selling SARM products as unapproved new drugs (FDA warning letter to Titan SARMs LLC, 12 December 2025). What is sold as YK-11 in liquid or capsule form is a research chemical of unverified content; across SARM-marketed products tested in one analysis, only 52 percent contained any SARM (PMID: 29183075).
IUPAC Name
Not yet available
CAS Number
1370003-76-1
Molecular Formula
C25H34O6
Molecular Mass
430.5 g/mol
Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser.
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser.
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
No sourced clinical contraindications exist because there are no human studies. Mechanism-based: as an androgen receptor agonist it should be avoided in pregnancy because of the risk of virilizing a female fetus, and in anyone with known or suspected prostate cancer. The rat neurotoxicity findings are a mechanism-based reason for caution in general (PMID: 37468001, PMID: 38521455). Athletes in tested sport must avoid it, since it is prohibited at all times (PMID: 28137616).
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$79.99
up to $84.99
$0.1700
1
2
capsule, liquid
| Vendor | Product | Form | Qty | Price | $/mg | Coupon | |
|---|---|---|---|---|---|---|---|
![]() |
YK-11 capsules (60) | capsule | 60 capsules● In Stock | $79.99BEST | — | — | |
![]() |
YK-11 50 mg/mL, 10 mL | liquid | 10 mL (50 mg/mL)● In Stock | $84.99VALUE | $0.170 | — |
Tracking since Sep 7, 2026 · 2 data points
How we score these vendors
Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.
ACE-031 (international nonproprietary name ramatercept) is a dimeric fusion protein that joins the extracellular domain of human activin receptor type IIB to the Fc region of human IgG1, developed by Acceleron Pharma as a decoy receptor that traps myostatin and related growth factors before they can suppress muscle growth (PMID: 27462804, PMID: 40312924).
ITPP (myo-inositol trispyrophosphate, sometimes written myo-inositol tripyrophosphate or OXY111A in NormOxys trial documents) is a small-molecule allosteric effector of hemoglobin designed to increase the amount of oxygen red blood cells release to tissues.
LGD-4033, usually sold as ligandrol, is a nonsteroidal selective androgen receptor modulator that Viking Therapeutics took into clinical development under the code VK5211 (NCT02578095).
Ostarine is the market name for enobosarm, a nonsteroidal selective androgen receptor modulator first developed by GTx Inc under the codes GTx-024, MK-2866 and S-22.
PEG-MGF (Pegylated Mechano Growth Factor) is a synthetic, PEGylated form of Mechano Growth Factor (MGF) — an alternatively spliced variant of IGF-1 produced locally in muscle and other tissues in response to mechanical loading or damage.
RAD-140, sold as testolone and given the international nonproprietary name vosilasarm, is a nonsteroidal selective androgen receptor modulator developed at Radius Health, whose scientists reported the first-in-human trial (PMID: 34565686), and first described in the medicinal chemistry literature as a compound with an oxadiazole core designed for oral androgen receptor activity with tissue selectivity (PMID: 24900290).
View Full Dosage Guide →
Protocols, calculator & safety for YK-11
0 PubMed results
Data Completeness
63%COA Verification
0
Verified COAs
1
Vendors w/ COA
Latest test: 9/16/2026
Half-Life
Not established. In a human elimination study using deuterium-labeled YK-11, no intact parent compound was seen in urine; unconjugated metabolites disappeared within 24 hours and glucuronidated and sulfated metabolites remained traceable beyond 48 hours (PMID: 30379415)
Molecular Weight
430.5 g/mol
Administration
Oral
CAS Number
1370003-76-1
Trial Phase
Preclinical
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
YK-11 is a synthetic steroid, not a nonsteroidal SARM, despite being sold alongside them. Its full chemical name is methyl (17alpha,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylate, and it was described by an academic group at Toho University in Japan rather than by a pharmaceutical company. It has never entered clinical development. There is no company behind it, no investigational new drug program, and no human trial of any kind.
The original 2011 report showed that YK-11 activates the androgen receptor as a partial agonist in a reporter assay, moves the receptor into the nucleus, and does so without inducing the amino-terminal to carboxy-terminal interaction that full androgens produce. In androgen receptor positive human breast cancer cells it acted as a gene-selective agonist, so its effect relative to dihydrotestosterone depended on which gene was measured (PMID: 21372378). Later work from the same group traced that selectivity to different DNA binding and different co-regulator recruitment compared with dihydrotestosterone (PMID: 36030969).
The claim that YK-11 is a myostatin inhibitor comes from one cell study. In mouse C2C12 myoblasts, YK-11 induced expression of follistatin, a protein that binds and neutralizes myostatin, and the resulting myogenic differentiation was reversed by an anti-follistatin antibody (PMID: 23995658). That is an indirect, cell-culture result in mouse cells. There is no published evidence that YK-11 binds or inhibits myostatin directly, and no human data on myostatin or follistatin after taking it. Other preclinical results include increased proliferation and mineralization in mouse MC3T3-E1 osteoblast cells (PMID: 29491216), improved osteogenic differentiation of rat bone marrow stromal cells and repair of rat cranial bone defects (PMID: 39660819), and reduced inflammatory markers and mortality in mice with bacterial sepsis (PMID: 33588136).
The safety data that do exist are unfavorable and come from rats. In male Wistar rats, five weeks of YK-11 increased oxidative stress and impaired every measured marker of mitochondrial function in the hippocampus, and exercise did not reverse those changes (PMID: 37468001). A follow-up study in rats reported impaired memory consolidation, downregulation of BDNF signaling, higher pro-inflammatory interleukin 1 beta and interleukin 6, lower interleukin 10, and activation of an apoptotic cascade in the hippocampus (PMID: 38521455). There is no human safety data at all.
In sport, YK-11 is prohibited. It is named in the World Anti-Doping Agency anabolic agents class alongside the nonsteroidal SARMs (PMID: 28137616), its mass spectrometric behavior and human urinary metabolites have been characterized for testing (PMID: 28440570, PMID: 30379415), and it has been reported in an actual doping control sample (PMID: 37946705). FDA has named YK-11 in warning letters to firms selling SARM products as unapproved new drugs (FDA warning letter to Titan SARMs LLC, 12 December 2025). What is sold as YK-11 in liquid or capsule form is a research chemical of unverified content; across SARM-marketed products tested in one analysis, only 52 percent contained any SARM (PMID: 29183075).
YK-11 is available in capsule, liquid forms.
Compare prices, payment methods, shipping, and COA scores across 1 vendor.
1 of the vendors BodyHackGuide tracks list YK-11 (2 listings). Among BodyHackGuide's YK-11 listings recorded as in stock with a milligram count, the lowest price per milligram is $0.170/mg at Disguised Alpha and the median is $0.170/mg. The YK-11 prices on BodyHackGuide are vendors' listed prices as BodyHackGuide last recorded them, not transactions; the most recent recorded change to a YK-11 listing is dated 7 September 2026.
BodyHackGuide holds 1 third-party certificate record for YK-11, from . No editor has read any of BodyHackGuide's 1 certificate record for YK-11. The laboratory named on BodyHackGuide's YK-11 certificate record is Freedom Diagnostics Testing, and the test date on it is 29 July 2026. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor and links to each record that has its own page.
Performance
View productPerformance
View productPerformance
View productMetabolic
View productACE-031 (international nonproprietary name ramatercept) is a dimeric fusion protein that joins the extracellular domain of human activin receptor type IIB to the Fc region of human IgG1, developed by Acceleron Pharma as a decoy receptor that traps myostatin and related growth factors before they can suppress muscle growth (PMID: 27462804, PMID: 40312924).
ITPP (myo-inositol trispyrophosphate, sometimes written myo-inositol tripyrophosphate or OXY111A in NormOxys trial documents) is a small-molecule allosteric effector of hemoglobin designed to increase the amount of oxygen red blood cells release to tissues.
LGD-4033, usually sold as ligandrol, is a nonsteroidal selective androgen receptor modulator that Viking Therapeutics took into clinical development under the code VK5211 (NCT02578095).
Ostarine is the market name for enobosarm, a nonsteroidal selective androgen receptor modulator first developed by GTx Inc under the codes GTx-024, MK-2866 and S-22.
PEG-MGF (Pegylated Mechano Growth Factor) is a synthetic, PEGylated form of Mechano Growth Factor (MGF) — an alternatively spliced variant of IGF-1 produced locally in muscle and other tissues in response to mechanical loading or damage.
RAD-140, sold as testolone and given the international nonproprietary name vosilasarm, is a nonsteroidal selective androgen receptor modulator developed at Radius Health, whose scientists reported the first-in-human trial (PMID: 34565686), and first described in the medicinal chemistry literature as a compound with an oxadiazole core designed for oral androgen receptor activity with tissue selectivity (PMID: 24900290).
Free 2026 Peptide Cheat Sheet (PDF)
38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.